Multifaceted genomic risk for brain function in schizophrenia

NeuroImage

Volumn 61, Issue 4, 2012, Pages 866-875

  Chen, Jiayu ^a,b   Calhoun, Vince D ^a,b,c,d,e   Pearlson, Godfrey D ^d,e   Ehrlich, Stefan ^g,h   Turner, Jessica A ^b   Ho, Beng Choon ⁱ   Wassink, Thomas H ⁱ   Michael, Andrew M ^b,f   Liu, Jingyu ^a,b  

^a University of New Mexico   (United States)

^b MIND RESEARCH NETWORK   (United States)

^c UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^d INSTITUTE OF LIVING   (United States)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f ROCHESTER INSTITUTE OF TECHNOLOGY   (United States)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

^h UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

ⁱ UNIVERSITY OF IOWA   (United States)

Author keywords

FMRI; Multivariate; Parallel ICA; Schizophrenia; SNP

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; DOPAMINE RECEPTOR; GLUTAMATE RECEPTOR; NEU DIFFERENTIATION FACTOR; NEUROTRANSMITTER;

ADULT; ALLELE; ARTICLE; BRAIN FUNCTION; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE PREDISPOSITION; ELECTROENCEPHALOGRAM; FEMALE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GENE IDENTIFICATION; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC CODE; GENETIC RISK; HUMAN; IMAGE ANALYSIS; IMAGE DISPLAY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NEUROIMAGING; NEUROPATHOLOGY; POSTCENTRAL GYRUS; PRIORITY JOURNAL; SCHIZOPHRENIA; SENSORIMOTOR FUNCTION; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TASK PERFORMANCE;

ADOLESCENT; ADULT; BRAIN; BRAIN MAPPING; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; SCHIZOPHRENIA; SYNAPTIC TRANSMISSION; YOUNG ADULT;

EID: 84861334676     PISSN: 10538119     EISSN: 10959572     Source Type: Journal    
DOI: 10.1016/j.neuroimage.2012.03.022     Document Type: Article

References (74)

1. Aalto S., Ihalainen J., Hirvonen J., Kajander J., Scheinin H., Tanila H., et al. Cortical glutamate-dopamine interaction and ketamine-induced psychotic symptoms in man. Psychopharmacology 2005, 182:375-383.
2. Abbott C., Juarez M., White T., Gollub R.L., Pearlson G.D., Bustillo J., et al. Antipsychotic dose and diminished neural modulation: a multi-site fMRI study. Prog. Neuropsychopharmacol. Biol. Psychiatry 2011, 35:473-482.
3. Akbarian S., Kim J.J., Potkin S.G., Hagman J.O., Tafazzoli A., Bunney W.E., et al. Gene-expression for glutamic-acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics. Arch. Gen. Psychiatry 1995, 52:258-266.
4. Allen N.C., Bagade S., McQueen M.B., Ioannidis J.P.A., Kavvoura F.K., Khoury M.J., et al. Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database. Nat. Genet. 2008, 40:827-834.
5. Anderson C.A., Pettersson F.H., Clarke G.M., Cardon L.R., Morris A.P., Zondervan K.T. Data quality control in genetic case-control association studies. Nat. Protoc. 2010, 5:1564-1573.
6. Andreasen N.C. The Scale for the Assessment of Negative Symptoms (SANS) 1983, The University of Iowa, Iowa City, IA.
7. Andreasen N.C. The Scale for the Assessment of Negative Symptoms (SAPS) 1984, The University of Iowa, Iowa City, IA.
8. Andreasen N.C., Flaum M., Arndt S. The comprehensive assessment of symptoms and history (Cash) - an instrument for assessing diagnosis and psychopathology. Arch. Gen. Psychiatry 1992, 49:615-623.
9. Neurotransmitters 2001, Sinauer, Sunderland, MA. 2nd ed. G.J. Augustine (Ed.).
10. Bell A.J., Sejnowski T.J. An information maximization approach to blind separation and blind deconvolution. Neural Comput. 1995, 7:1129-1159.
11. Bilder R.M., Goldman R.S., Robinson D., Reiter G., Bell L., Bates J.A., et al. Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates. Am. J. Psychiatry 2000, 157:549-559.
12. Cardno A.G., Gottesman I.I. Twin studies of schizophrenia: from bow-and-arrow concordances to star wars mx and functional genomics. Am J. Med. Genet. 2000, 97:12-17.
13. Cohen T.J., Waddell D.S., Barrientos T., Lu Z., Feng G., Cox G.A., et al. The histone deacetylase HDAC4 connects neural activity to muscle transcriptional reprogramming. J. Biol. Chem. 2007, 282:33752-33759.
14. Duan J.B., Sanders A.R., Gejman P.V. Genome-wide approaches to schizophrenia. Brain Res. Bull. 2010, 83:93-102.
15. Fenton W.S., Wyatt R.J., Mcglashan T.H. Risk-factors for spontaneous dyskinesia in schizophrenia. Arch. Gen. Psychiatry 1994, 51:643-650.
16. First M.B., Gibbon M., Spitzer R.L., Williams J.B.W., Benjamin L.S. Structured clinical interview for DSM-IV axis II personality disorders, (SCID-II) 1997, American Psychiatric Press, Washington, DC. 4th ed.
17. Freire L., Mangin J.F. Motion correction algorithms may create spurious brain activations in the absence of subject motion. NeuroImage 2001, 14:709-722.
18. Freire L., Roche A., Mangin J.F. What is the best similarity measure for motion correction in fMRI time series?. IEEE Trans. Med. Imaging 2002, 21:470-484.
19. Friston K.J., Ashburner J., Frith C.D., Poline J.B., Heather J.D., Frackowiak R.S.J. Spatial registration and normalization of images. Hum. Brain Mapp. 1995, 3:165-189.
20. Funabiki K., Mishina M., Hirano T. Retarded vestibular compensation in mutant mice deficient in delta 2 glutamate receptor subunit. Neuroreport 1995, 7:189-192.
21. Gaser C., Volz H.P., Kiebel S., Riehemann S., Sauer H. Detecting structural changes in whole brain based on nonlinear deformations - application to schizophrenia research. NeuroImage 1999, 10:107-113.
22. Giuliani N.R., Calhoun V.D., Pearlson G.D., Francis A., Buchanan R.W. Voxel-based morphometry versus region of interest: a comparison of two methods for analyzing gray matter differences in schizophrenia. Schizophr. Res. 2005, 74:135-147.
23. Glahn D.C., Laird A.R., Ellison-Wright I., Thelen S.M., Robinson J.L., Lancaster J.L., et al. Meta-analysis of gray matter anomalies in schizophrenia: application of anatomic likelihood estimation and network analysis. Biol. Psychiatry 2008, 64:774-781.
24. Goodman A.B. Three independent lines of evidence suggest retinoids as causal to schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:7240-7244.
25. Gottesman I.I., Gould T.D. The endophenotype concept in psychiatry: etymology and strategic intentions. Am. J. Psychiatry 2003, 160:636-645.
26. Gottesman I.I., Shields J. A polygenic theory of schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 1967, 58:199-205.
27. Guidotti A., Auta J., Davis J.M., Gerevini V.D., Dwivedi Y., Grayson D.R., et al. Decrease in reelin and glutamic acid decarboxylase(67) (GAD(67)) expression in schizophrenia and bipolar disorder - a postmortem brain study. Arch. Gen. Psychiatry 2000, 57:1061-1069.
28. Gurevich E.V., Bordelon Y., Shapiro R.M., Arnold S.E., Gur R.E., Joyce J.N. Mesolimbic dopamine D-3 receptors and use of antipsychotics in patients with schizophrenia - a postmortem study. Arch. Gen. Psychiatry 1997, 54:225-232.
29. Harrison P.J., Owen M.J. Genes for schizophrenia? Recent findings and their pathophysiological implications. Lancet 2003, 361:417-419.
30. Harrison B.J., Yucel M., Pujol J., Pantelis C. Task-induced deactivation of midline cortical regions in schizophrenia assessed with fMRI. Schizophr. Res. 2007, 91:82-86.
31. Honer W.G., Kopala L.C., Rabinowitz J. Extrapyramidal symptoms and signs in first-episode, antipsychotic exposed and non-exposed patients with schizophrenia or related psychotic illness. J. Psychopharmacol. 2005, 19:277-285.
32. Huang D.W., Sherman B.T., Lempicki R.A. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 2009, 37:1-13.
33. Huang D.W., Sherman B.T., Lempicki R.A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 2009, 4:44-57.
34. Kao W.T., Wang Y.H., Kleinman J.E., Lipska B.K., Hyde T.M., Weinberger D.R., et al. Common genetic variation in Neuregulin 3 (NRG3) influences risk for schizophrenia and impacts NRG3 expression in human brain. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:15619-15624.
35. Kashiwabuchi N., Ikeda K., Araki K., Hirano T., Shibuki K., Takayama C., et al. Impairment of motor coordination, purkinje-cell synapse formation, and cerebellar long-term depression in glur-delta-2 mutant mice. Cell 1995, 81:245-252.
36. Kiehl K.A., Stevens M.C., Celone K., Kurtz M., Krystal J.H. Abnormal hemodynamics in schizophrenia during an auditory oddball task. Biol. Psychiatry 2005, 57:1029-1040.
37. Kim D.I., Sui J., Rachakonda S., White T., Manoach D.S., Clark V.P., et al. Identification of imaging biomarkers in schizophrenia: a coefficient-constrained independent component analysis of the mind multi-site schizophrenia study. Neuroinformatics 2010, 8:213-229.
38. Kishimoto Y., Kawahara S., Suzuki M., Mori H., Mishina M., Kirino Y. Classical eyeblink conditioning in glutamate receptor subunit delta 2 mutant mice is impaired in the delay paradigm but not in the trace paradigm. Eur. J. Neurosci. 2001, 13:1249-1253.
39. Kullmann D.N. Neurological channelopathies. Annu. Rev. Neurosci. 2010, 33(33):151-172.
40. Kuperberg G.R., Broome M.R., McGuire P.K., David A.S., Eddy M., Ozawa F., et al. Regionally localized thinning of the cerebral cortex in schizophrenia. Arch. Gen. Psychiatry 2003, 60:878-888.
41. Lawrie S.M., Whalley H.C., Job D.E., Johnstone E.C. Structural and functional abnormalities of the amygdala in schizophrenia. Amygdala in Brain Function: Bacic and Clinical Approaches 2003, 985:445-460.
42. Li B., Woo R.S., Mei L., Malinow R. The neuregulin-1 receptor ErbB4 controls glutamatergic synapse maturation and plasticity. Neuron 2007, 54:583-597.
43. Li Y.O., Adali T., Calhoun V.D. Estimating the number of independent components for functional magnetic resonance imaging data. Hum. Brain Mapp. 2007, 28:1251-1266.
44. Liu J., Bixler J.N., Calhoun V.D. A multimodality ICA study - integrating genomic single nucleotide polymorphisms with functional neuroimaging data. 2008 IEEE International Conference on Bioinformatics and Biomedicine Workshops, Philadelphia, PA 2008, 151-157.
45. Liu J., Pearlson G., Windemuth A., Ruano G., Perrone-Bizzozero N.I., Calhoun V. Combining fMRI and SNP data to investigate connections between brain function and genetics using parallel ICA. Hum. Brain Mapp. 2009, 30:241-255.
46. McDonald C., Marshall N., Sham P.C., Bullmore E.T., Schulze K., Chapple B., et al. Regional brain morphometry in patients with schizophrenia or bipolar disorder and their unaffected relatives. Am. J. Psychiatry 2006, 163:478-487.
47. Meda S.A., Jagannathan K., Gelernter J., Calhoun V.D., Liu J.Y., Stevens M.C., et al. A pilot multivariate parallel ICA study to investigate differential linkage between neural networks and genetic profiles in schizophrenia. NeuroImage 2010, 53:1007-1015.
48. Minzenberg M.J., Laird A.R., Thelen S., Carter C.S., Glahn D.C. Meta-analysis of 41 functional neuroimaging studies of executive function in schizophrenia. Arch. Gen. Psychiatry 2009, 66:811-822.
49. Mittal V.A., Neumann C., Saczawa M., Walker E.F. Longitudinal progression of movement abnormalities in relation to psychotic symptoms in adolescents at high risk of schizophrenia. Arch. Gen. Psychiatry 2008, 65:165-171.
50. Miyata M., Kishimoto Y., Tanaka M., Hashimoto K., Hirashima N., Murata Y., et al. A role for myosin Va in cerebellar plasticity and motor learning: a possible mechanism underlying neurological disorder in myosin Va disease. J. Neurosci. 2011, 31:6067-6078.
51. Narr K.L., Bilder R.M., Toga A.W., Woods R.P., Rex D.E., Szeszko P.R., et al. Mapping cortical thickness and gray matter concentration in first episode schizophrenia. Cereb. Cortex 2005, 15:708-719.
52. Narr K.L., Toga A.W., Szeszko P., Thompson P.M., Woods R.P., Robinson D., et al. Cortical thinning in cingulate and occipital cortices in first episode schizophrenia. Biol. Psychiatry 2005, 58:32-40.
53. Neckelmann G., Specht K., Lund A., Ersland L., Smievoll A.I., Neckelmann D., et al. MR morphometry analysis of grey matter volume reduction in schizophrenia: association with hallucinations. Int. J. Neurosci. 2006, 116:9-23.
54. Nelson M.D., Saykin A.J., Flashman L.A., Riordan H.J. Hippocampal volume reduction in schizophrenia as assessed by magnetic resonance imaging - a meta-analytic study. Arch. Gen. Psychiatry 1998, 55:433-440.
55. Oken R.J., Schulzer M. At issue: schizophrenia and rheumatoid arthritis: the negative association revisited. Schizophr. Bull. 1999, 25:625-638.
56. Omkumar R.V., Kiely M.J., Rosenstein A.J., Min K.T., Kennedy M.B. Identification of a phosphorylation site for calcium/calmodulindependent protein kinase II in the NR2B subunit of the N-methyl-D-aspartate receptor. J. Biol. Chem. 1996, 271:31670-31678.
57. Paulus M.P., Hozack N.E., Zauscher B.E., Frank L., Brown G.G., McDowell J., et al. Parietal dysfunction is associated with increased outcome-related decision-making in schizophrenia patients. Biol. Psychiatry 2002, 51:995-1004.
58. Prata D.P., Mechelli A., Fu C.H.Y., Picchioni M., Toulopoulou T., Bramon E., et al. Epistasis between the DAT 3' UTR VNTR and the COMT Val158Met SNP on cortical function in healthy subjects and patients with schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:13600-13605.
59. Price A.L., Patterson N.J., Plenge R.M., Weinblatt M.E., Shadick N.A., Reich D. Principal components analysis corrects for stratification in genome-wide association studies. Nat. Genet. 2006, 38:904-909.
60. Purcell S., Neale B., Todd-Brown K., Thomas L., Ferreira M.A.R., Bender D., et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet. 2007, 81:559-575.
61. Purcell S.M., Wray N.R., Stone J.L., Visscher P.M., O'Donovan M.C., Sullivan P.F., et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 2009, 460:748-752.
62. Rapoport J.L., Addington A.M., Frangou S., Psych M. The neurodevelopmental model of schizophrenia: update 2005. Mol. Psychiatry 2005, 10:434-449.
63. Scales S.J., Hesser B.A., Masuda E.S., Scheller R.H. Amisyn, a novel syntaxin-binding protein that may regulate SNARE complex assembly. J. Biol. Chem. 2002, 277:28271-28279.
64. Schroder J., Wenz F., Schad L.R., Baudendistel K., Knopp M.V. Sensorimotor cortex and supplementary motor area changes in schizophrenia - a study with functional magnetic-resonance-imaging. Br. J. Psychiatry 1995, 167:197-201.
65. Schroder J., Essig M., Baudendistel K., Jahn T., Gerdsen I., Stockert A., et al. Motor dysfunction and sensorimotor cortex activation changes in schizophrenia: a study with functional magnetic resonance imaging. NeuroImage 1999, 9:81-87.
66. Shergill S.S., Bullmore E., Simmons A., Murray R., McGuire P. Functional anatomy of auditory verbal imagery in schizophrenic patients with auditory hallucinations. Am. J. Psychiatry 2000, 157:1691-1693.
67. Strack S., Zaucha J.A., Ebner F.F., Colbran R.J., Wadzinski B.E. Brain protein phosphatase 2A: developmental regulation and distinct cellular and subcellular localization by B subunits. J. Comp. Neurol. 1998, 392:515-527.
68. Straub R.E., Lipska B.K., Egan M.F., Goldberg T.E., Callicott J.H., Mayhew M.B., et al. Allelic variation in GAD1 (GAD(67)) is associated with schizophrenia and influences cortical function and gene expression. Mol. Psychiatry 2007, 12:854-869.
69. Sun J., Maller J.J., Guo L., Fitzgerald P.B. Superior temporal gyrus volume change in schizophrenia: a review on region of interest volumetric studies. Brain Res. Rev. 2009, 61:14-32.
70. Suzuki A., Yamada R., Chang X., Tokuhiro S., Sawada T., Suzuki M., et al. Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis. Nat. Genet. 2003, 34:395-402.
71. Volk D.W., Austin M.C., Pierri J.N., Sampson A.R., Lewis D.A. Decreased glutamic acid decarboxylase(67) messenger RNA expression in a subset of prefrontal cortical gamma-aminobutyric acid neurons in subjects with schizophrenia. Arch. Gen. Psychiatry 2000, 57:237-245.
72. Vollenweider F.X., Vontobel P., Oye I., Hell D., Leenders K.L. Effects of (S)-ketamine on striatal dopamine: a [11C]raclopride PET study of a model psychosis in humans. J. Psychiatr. Res. 2000, 34:35-43.
73. Walker E.F., Savoie T., Davis D. Neuromotor precursors of schizophrenia. Schizophr. Bull. 1994, 20:441-451.
74. Woo R.S., Li X.M., Tao Y.M., Carpenter-Hyland E., Huang Y.Z., Weber J., et al. Neuregulin-1 enhances depolarization-induced GABA release. Neuron 2007, 54:599-610.